Arcutis Biotherapeutics Inc (ARQT) - Net Assets
Based on the latest financial reports, Arcutis Biotherapeutics Inc (ARQT) has net assets worth $189.65 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($460.00 Million) and total liabilities ($270.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Arcutis Biotherapeutics Inc (ARQT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $189.65 Million |
| % of Total Assets | 41.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | -36.35% |
| 10-Year Change | N/A |
| Growth Volatility | 73.82 |
Arcutis Biotherapeutics Inc - Net Assets Trend (2017–2025)
This chart illustrates how Arcutis Biotherapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Arcutis Biotherapeutics Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Arcutis Biotherapeutics Inc (2017–2025)
The table below shows the annual net assets of Arcutis Biotherapeutics Inc from 2017 to 2025. For live valuation and market cap data, see Arcutis Biotherapeutics Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $189.48 Million | +20.27% |
| 2024-12-31 | $157.54 Million | +77.68% |
| 2023-12-31 | $88.67 Million | -57.69% |
| 2022-12-31 | $209.58 Million | -29.59% |
| 2021-12-31 | $297.68 Million | +10.00% |
| 2020-12-31 | $270.62 Million | +166.72% |
| 2019-12-31 | $101.46 Million | +522.99% |
| 2018-12-31 | $-23.99 Million | -380.41% |
| 2017-12-31 | $-4.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arcutis Biotherapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 113306300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | 0.01% |
| Other Comprehensive Income | $-44.00K | -0.02% |
| Other Components | $1.33 Billion | 700.66% |
| Total Equity | $189.48 Million | 100.00% |
Arcutis Biotherapeutics Inc Competitors by Market Cap
The table below lists competitors of Arcutis Biotherapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hunan Changyuan Lico Co Ltd
SHG:688779
|
$2.64 Billion |
|
YiDong Electronics Technology Co. Ltd.
SHE:301123
|
$2.64 Billion |
|
Livzon Pharmaceutical Group Inc
SHE:000513
|
$2.64 Billion |
|
CSSC Steel Structure Engineering Co Ltd
SHG:600072
|
$2.65 Billion |
|
Sichuan Development Lomon Co Ltd
SHE:002312
|
$2.64 Billion |
|
Zhongfu Straits Pingtan Development Co Ltd
SHE:000592
|
$2.64 Billion |
|
Sumitomo Chemical India Limited
NSE:SUMICHEM
|
$2.64 Billion |
|
Corporación Inmobiliaria Vesta, S.A.B de C.V.
NYSE:VTMX
|
$2.64 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arcutis Biotherapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 157,541,000 to 189,479,000, a change of 31,938,000 (20.3%).
- Net loss of 16,140,999 reduced equity.
- Other comprehensive income decreased equity by 37,000.
- Other factors increased equity by 48,115,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.14 Million | -8.52% |
| Other Comprehensive Income | $-37.00K | -0.02% |
| Other Changes | $48.12 Million | +25.39% |
| Total Change | $- | 20.27% |
Book Value vs Market Value Analysis
This analysis compares Arcutis Biotherapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.18x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-4.73 | $21.11 | x |
| 2018-12-31 | $-0.66 | $21.11 | x |
| 2019-12-31 | $2.66 | $21.11 | x |
| 2020-12-31 | $7.59 | $21.11 | x |
| 2021-12-31 | $6.03 | $21.11 | x |
| 2022-12-31 | $3.81 | $21.11 | x |
| 2023-12-31 | $1.28 | $21.11 | x |
| 2024-12-31 | $1.30 | $21.11 | x |
| 2025-12-31 | $1.49 | $21.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arcutis Biotherapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.29%
- • Asset Turnover: 0.87x
- • Equity Multiplier: 2.29x
- Recent ROE (-8.52%) is above the historical average (-78.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.48 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.86 Million |
| 2019 | -41.39% | 0.00% | 0.00x | 1.05x | $-52.14 Million |
| 2020 | -50.14% | 0.00% | 0.00x | 1.10x | $-162.74 Million |
| 2021 | -69.17% | 0.00% | 0.00x | 1.37x | $-235.67 Million |
| 2022 | -148.61% | -8449.76% | 0.01x | 2.14x | $-332.42 Million |
| 2023 | -295.65% | -439.79% | 0.17x | 3.85x | $-271.01 Million |
| 2024 | -88.89% | -71.25% | 0.56x | 2.21x | $-155.79 Million |
| 2025 | -8.52% | -4.29% | 0.87x | 2.29x | $-35.09 Million |
Industry Comparison
This section compares Arcutis Biotherapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $190,374,900
- Average return on equity (ROE) among peers: -53.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arcutis Biotherapeutics Inc (ARQT) | $189.65 Million | 0.00% | 1.43x | $2.64 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $91.45 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $312.29 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $174.79 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $823.18 Million |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $540.89 Million | -31.04% | 0.29x | $3.64 Billion |
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a po… Read more